Equity Overview
Price & Market Data
Price: $3.05
Daily Change: -$0.11 / 3.61%
Daily Range: $3.05 - $3.19
Market Cap: $15,323,471
Daily Volume: 50,320
Performance Metrics
1 Week: -9.06%
1 Month: -67.40%
3 Months: -71.15%
6 Months: -54.93%
1 Year: -71.52%
YTD: -71.52%
Company Details
Employees: 25
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.